Tolvaptan: a new therapeutic agent.
Georgios Aperis1, Polichronis Alivanis
1Department of Nephrology, General Hospital of Rhodes, Greece.
Reviews on Recent Clinical Trials
|September 28, 2010
Summary
Tolvaptan, a V(2) receptor antagonist, treats hyponatremia and heart failure by inducing diuresis. While effective short-term, long-term benefits require further study, and it may also benefit Autosomal Dominant Polycystic Kidney Disease (ADPKD).
Area of Science:
- Pharmacology
- Nephrology
- Cardiology
Background:
- Hyponatremia, often linked to SIADH, cirrhosis, or heart failure, presents management challenges.
- Tolvaptan is a novel V(2) receptor antagonist that promotes aquaresis.
- Its efficacy and safety profile are under investigation for various clinical conditions.
Purpose of the Study:
- To review the therapeutic applications of tolvaptan.
- To discuss its mechanism of action and clinical outcomes.
- To highlight its potential in treating hyponatremia, heart failure, and ADPKD.
Main Methods:
- Review of clinical trials and studies on tolvaptan.
- Analysis of tolvaptan's pharmacological properties as a V(2) receptor antagonist.
- Examination of its efficacy in normovolemic/hypervolemic hyponatremia, heart failure, and ADPKD.
Main Results:
- Tolvaptan is approved for hyponatremia associated with SIADH, cirrhosis, and heart failure; contraindicated in hypovolemic hyponatremia.
- Short-term use shows benefits in acute decompensated heart failure, improving symptoms and mortality.
- Long-term mortality benefits remain controversial; potential role in ADPKD is under investigation.
Conclusions:
- Tolvaptan offers a new therapeutic avenue for specific hyponatremia types and acute heart failure.
- Careful monitoring and awareness of drug interactions (CYP3A4 metabolism) are essential.
- Further research is needed to clarify long-term effects and its role in ADPKD.
More Related Videos
06:34Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
Published on: November 29, 2024
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
Related Concept Videos
01:16Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...